


A Formal Enantioselective Total Synthesis  
of FR901483Hao-Hua Huo,<sup>†</sup> Hong-Kui Zhang,<sup>†</sup> Xiao-Er Xia,<sup>†</sup> and Pei-Qiang Huang<sup>\*†‡</sup>*Department of Chemistry, College of Chemistry and Chemical Engineering,  
Xiamen University, Xiamen, Fujian 361005, P. R. China, and State Key Laboratory of  
Bioorganic and Natural Products Chemistry, 354 Fenglin Lu, Shanghai 200032, P. R. China*

pqhuang@xmu.edu.cn

Received August 3, 2012

## ABSTRACT




A formal enantioselective total synthesis of the potent immunosuppressant FR901483 (**1**) has been accomplished. Our approach features the use of chiron **6** as the starting material, the application of the one-pot amide reductive bisalkylation method to construct the chiral aza-quaternary center (dr = 9:1), regio- and diastereoselective intramolecular aldol reaction to build the bridged ring, and ring closing metathesis to form the 3-pyrrolin-2-one ring.

FR901483 (**1**, Figure 1) is a potent immunosuppressant isolated from the fermentation broth of the *Cladobotryum* sp. No. 11231 by a research group at the Japan Fujisawa Pharmaceutical Company in 1996.<sup>1</sup> Due to its promising

biological activity and challenging structure, this molecule has attracted the attention of many research groups. To date, six enantioselective total syntheses/formal total syntheses<sup>2,3</sup> and numerous synthetic studies<sup>4,5</sup> toward FR901483 (**1**) have been reported. As a continuation

<sup>†</sup> Xiamen University.<sup>‡</sup> State Key Laboratory of Bioorganic and Natural Products Chemistry.(1) Sakamoto, K.; Tsujii, E.; Abe, F.; Nakanishi, T.; Yamashita, M.; Shigematsu, N.; Izumi, S.; Okuhara, M. *J. Antibiot.* **1996**, *49*, 37–44.(2) For enantioselective total syntheses, see: (a) Snider, B. B.; Lin, H. *J. Am. Chem. Soc.* **1999**, *121*, 7778–7786. (b) Scheffler, G.; Seike, H.; Sorensen, E. J. *Angew. Chem., Int. Ed.* **2000**, *39*, 4593–4596. (c) Ousmer, M.; Braun, N. A.; Ciufolini, M. A. *Org. Lett.* **2001**, *3*, 765–767. (d) Ousmer, M.; Braun, N. A.; Bavoux, C.; Perrin, M.; Ciufolini, M. A. *J. Am. Chem. Soc.* **2001**, *123*, 7534–7538. (e) Ma, A.-J.; Tu, Y.-Q.; Peng, J.-B.; Dou, Q.-Y.; Hou, S.-H.; Zhang, F.-M.; Wang, S.-H. *Org. Lett.* **2012**, *14*, 3604–3607. For formal total syntheses, see: (f) Brummond, K. M.; Hong, S. P. *J. Org. Chem.* **2005**, *70*, 907–916. (g) Carson, C. A.; Kerr, M. A. *Org. Lett.* **2009**, *11*, 777–779.(3) For racemic total syntheses, see: (a) Maeng, J.; Funk, R. L. *Org. Lett.* **2001**, *3*, 1125–1128. (b) Kan, T.; Fujimoto, T.; Ieda, S.; Asoh, Y.; Kitaoka, H.; Fukuyama, T. *Org. Lett.* **2004**, *6*, 2729–2731. (c) Ieda, S.; Asoh, Y.; Fujimoto, T.; Kitaoka, H.; Kan, T.; Fukuyama, T. *Heterocycles* **2009**, *79*, 721–738.(4) For enantioselective synthetic studies, see: (a) Puigbó, G.; Diaba, F.; Bonjoch, J. *Tetrahedron* **2003**, *59*, 2657–2665. (b) Diaba, F.; Ricou, E.; Solé, D.; Teixidó, E.; Valls, N.; Bonjoch, J. *ARKIVOC* **2007**, *4*, 320–330. (c) Kaden, S.; Reissig, H.-U. *Org. Lett.* **2006**, *8*, 4763–4766. (d) Seike, H.; Sorensen, E. J. *Synlett* **2008**, 695–701. (e) Ieda, S.; Kan, T.; Fukuyama, T. *Tetrahedron Lett.* **2010**, *51*, 4027–4029. (f) Puppala, M.; Murali, A.; Sundarababu, B. *Chem. Commun.* **2012**, *48*, 5778–5780.(5) For racemic synthetic studies, see: (a) Yamazaki, N.; Suzuki, H.; Kibayashi, C. *J. Org. Chem.* **1997**, *62*, 8280–8281. (b) Quirante, J.; Escolano, C.; Massot, M.; Bonjoch, J. *Tetrahedron* **1997**, *53*, 1391–1402. (c) Bonjoch, J.; Diaba, F.; Puigbó, G.; Solé, D.; Segarra, V.; Santamaria, L.; Beleta, J.; Ryder, H.; Palacios, J.-M. *Bioorg. Med. Chem.* **1999**, *7*, 2891–2897. (d) Wardrop, D. J.; Zhang, W. *Org. Lett.* **2001**, *3*, 2353–2356. (e) Brummond, K. M.; Lu, J.-L. *Org. Lett.* **2001**, *3*, 1347–1349. (f) Suzuki, H.; Yamazaki, N.; Kibayashi, C. *Tetrahedron Lett.* **2001**, *42*, 3013–3015. (g) Bonjoch, J.; Diaba, F.; Puigbó, G.; Peidró, E.; Solé, D. *Tetrahedron Lett.* **2003**, *44*, 8387–8390. (h) Kropf, J. E.; Meigh, I. C.; Bebbington, M. W. P.; Weinreb, S. M. *J. Org. Chem.* **2006**, *71*, 2046–2055. (i) Simila, S. T. M.; Martin, S. F. *J. Org. Chem.* **2007**, *72*, 5342–5349.(6) (a) Xu, C.-P.; Xiao, Z.-H.; Zhuo, B.-Q.; Wang, Y.-H.; Huang, P.-Q. *Chem. Commun.* **2010**, *46*, 7834–7836. (b) Xiao, K.-J.; Luo, J.-M.; Ye, K.-Y.; Wang, Y.; Huang, P.-Q. *Angew. Chem., Int. Ed.* **2010**, *49*, 3037–3040. (c) Xiao, K.-J.; Wang, Y.; Ye, K.-Y.; Huang, P.-Q. *Chem.—Eur. J.* **2010**, *16*, 12792–12796. (d) Liu, X.-K.; Zheng, X.; Ruan, Y.-P.; Ma, J.; Huang, P.-Q. *Org. Biomol. Chem.* **2012**, *10*, 1275–1284. (e) Liao, J.-C.; Xiao, K.-J.; Zheng, X.; Huang, P.-Q. *Tetrahedron* **2012**, *68*, 5297–5302. (f) Wang, Y.-H.; Ye, J.-L.; Wang, A.-E.; Huang, P.-Q. *Org. Biomol. Chem.* **2012**, *10*, 6504–6511. (g) Xiao, K.-J.; Wang, A.-E.; Huang, P.-Q. *Angew. Chem., Int. Ed.* **2012**, *51*, 8314–8317. (h) Xiao, K.-J.; Wang, A.-E.; Huang, Y.-H.; Huang, P.-Q. *Asian J. Org. Chem.* **2012**, *10*, 1002–1006.


of our endeavor to develop step-economical<sup>6</sup> and 3-benzyloxyglutarimide<sup>7</sup>-based synthetic methodologies for the asymmetric synthesis of piperidine ring-containing alkaloids,<sup>8</sup> we have embarked on the enantioselective total synthesis of FR901483. We report herein a formal enantioselective total synthesis of FR901483 (**1**).



**Figure 1.** Potent immunosuppressant FR901483 (**1**).

As illustrated retrosynthetically in Scheme 1 >, our synthetic plan is based on two key synthetic methodologies developed from our laboratory, namely, the use of chiron **6**<sup>8</sup> as the starting point and the amide reductive bisalkylation method<sup>6b</sup> for a one-pot conversion of piperidin-2-one **5** to piperidine **4** with the formation of two C–C bonds.

**Scheme 1.** Retrosynthetic Analysis of FR901483 (**1**)




The synthesis commenced with the partial and regioselective reduction<sup>8b</sup> of (*3R*)-benzyloxyglutarimide **6** with NaBH<sub>4</sub> followed by reductive dehydroxylation (BF<sub>3</sub>•OEt<sub>2</sub>, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>) via an iminium ion intermediate<sup>8a,c</sup> (Scheme 2). The subsequent bisalkylation of lactam<sup>6b</sup> **5** (Tf<sub>2</sub>O, DTBMP, CH<sub>2</sub>Cl<sub>2</sub>; then successive addition of two Grignard reagents) proceeded as planned to produce the desired lactam **4** in 75% yield. Remarkably, the reaction proceeded with high diastereoselectivity (*dr* = 9:1,

determined by <sup>1</sup>H NMR of the crude sample). The stereochemistry of the major diastereomer was deduced to be *trans* on the basis of the mechanistic consideration that the vinyl group approaches the iminium ion intermediate from the α-side opposing the benzyloxy group, which was confirmed at a latter stage. It is worth mentioning that, among various synthetic approaches for the synthesis of FR901483 (**1**), this is the first example utilizing the one-pot amide reductive bisalkylation method to construct the chiral aza-quaternary center.

The selective *O*-debenzylation of compound **4** was achieved by treatment of piperidine **4** (diastereomeric mixture) with lithium naphthalenide (LN)<sup>9</sup> in THF at –40 °C for 1 h, which gave, after chromatographic separation, the piperidin-3-ol **7** as a pure diastereomer in 85% yield.

**Scheme 2.** Stereoselective Synthesis of the Key Intermediate **7**



Next, the piperidin-3-ol **7** needed to be oxidized to the ketone **8** before the key intramolecular aldol ring closure reaction could be commenced. After unsuccessful trials with the Dess-Martin periodinane, and partial success with the Ley oxidation (35% yield), the Swern oxidation was attempted. It was found that by the use of an extreme excess of triethylamine, the desired ketone could be obtained in 90% yield [(COCl)<sub>2</sub> 6 equiv, DMSO 12 equiv, CH<sub>2</sub>Cl<sub>2</sub>, –78 °C, 1 h; and then NEt<sub>3</sub> 25 equiv]. After deacetalization of compound **8** with a 4 *N* HCl solution, the resulting keto-aldehyde, in the form of its hydrochloride salt, was heated with ethylene glycol (4.0 equiv)<sup>10</sup> and CSA (0.3 equiv) in toluene at 90 °C. The desired regioselective intramolecular aldol reaction took place smoothly with concomitant acetalization of the ketone to give compound **9** as the solely observable regio- and diastereomer in 53% yield (Scheme 3). The relative stereochemistry of **9** was established on the basis of the observed

(7) Ruan, Y.-P.; Wei, B.-G.; Xu, X.-Q.; Liu, G.; Yu, D.-S.; Liu, L.-X.; Huang, P.-Q. *Chirality* **2005**, *17*, 595–599.


(8) For recent examples, see: (a) Fu, R.; Ye, J.-L.; Dai, X.-J.; Ruan, Y.-P.; Huang, P.-Q. *J. Org. Chem.* **2010**, *75*, 4230–4243. (b) Yang, R.-F.; Huang, P.-Q. *Chem.—Eur. J.* **2010**, *16*, 10319–10322. (c) Tuo, S.-C.; Ye, J.-L.; Wang, A.-E.; Huang, S.-Y.; Huang, P.-Q. *Org. Lett.* **2011**, *13*, 5270–5273.

(9) Liu, H.-J.; Yip, J.; Shia, K.-S. *Tetrahedron Lett.* **1997**, *38*, 2253–2256.

(10) If the hydrochloride salt was neutralized and the mixture was heated in the absence of ethylene glycol, a regiomer aldol product was obtained in 65% yield as a single diastereomer.


strong correlation between the methine proton ( $\delta$  3.83) and the  $H_{eq}$  ( $\delta$  2.12), and a smaller correlation between the methine proton ( $\delta$  3.83) and the  $H_{ax}$  ( $\delta$  1.78) in its NOESY spectrum (Scheme 3).

**Scheme 3.** Synthesis and the Observed NOE Correlations of Compound **9**



After securing access to the bicyclic core **9**, the conversion of the latter to a precursor for the ring closing metathesis (RCM) reaction was investigated. Thus, the hydroxyl group was protected as its benzyl ether **10** (BnBr, NaH,  $Bu_4NI$ , DMF, 90% yield) (Scheme 4). Compound **10** was subjected to Pd-catalyzed *N*-deallylation [ $Pd(Ph_3P)_4$  (0.01 equiv), NDMBA (3 equiv),  $CH_2Cl_2$ , rt, 1 h),<sup>11</sup> and acryloylation (acryloyl chloride,  $NEt_3$ ,  $CH_2Cl_2$ , 0 °C, 30 min), which gave acrylamide **12** in 81% yield over two steps.

**Scheme 4.** Synthesis of the Acrylamide Derivative **12**




(11) (a) Garro-Helion, F.; Merzouk, A.; Guibé, F. *J. Org. Chem.* **1993**, *58*, 6109–6113. (b) Davies, S. G.; Fenwick, D. R. *Chem. Commun.* **1997**, 565–566.

(12) For reviews on the applications of the RCM reaction in the synthesis of lactams, see: (a) Hassan, H. M. A. *Chem. Commun.* **2010**, *46*, 9100–9106. (b) Deiters, A.; Martin, S. F. *Chem. Rev.* **2004**, *104*, 2199–2238. (c) Felpin, F. X.; Lebreton, J. *Eur. J. Org. Chem.* **2003**, 3693–3712. For a recent example, see: (d) Zhang, H.-K.; Li, X.; Huang, H.; Huang, P.-Q. *Sci. Sinica Chim.* **2011**, *41*, 732–740. *Sci. China Chem.* **2011**, *54*, 737–744 (in Chinese).

We next investigated the RCM reaction of **12**. Formation of  $\alpha,\beta$ -unsaturated lactams by the RCM reaction of acrylamides has been well documented using either Grubbs' first or second generation catalyst.<sup>12</sup> The reaction generally proceeded in  $CH_2Cl_2$ .<sup>5f,12</sup> However in our case all attempts to perform the RCM reaction of **12** by the use of the Grubbs first or second generation catalyst in  $CH_2Cl_2$  were unsuccessful. Considering the steric hindrance of the substrate, it was envisioned that a higher reaction temperature would favor the reaction. Indeed, when a toluene solution of acrylamide **12** and the Grubbs second generation catalyst (25%) was heated to 85 °C for 12 h, the desired cyclized product **13** was obtained in 30% yield, along with 60% of the recovered starting material. Remarkably, when the reaction (Grubbs II 25%, toluene, 85 °C) was run in the presence of 30% molar equiv of  $Ti(OiPr)_4$ ,<sup>13</sup> the desired cyclic core **13** was obtained in 92% yield (Scheme 5).

**Scheme 5.** Construction of the Tricyclic Core **13** by the RCM Reaction





Now we were in a position to undertake the functional group exchange and the functionalization of the core structure. Thus, acetal **13** was cleaved by treatment with a solution of 4 *N* HCl in acetone at reflux for 3 h to give the keto-lactam **3** in 85% yield (Scheme 6). Inversed addition<sup>3a</sup> of the enolate, generated from ketone **3** by deprotonation with KHMDS (1 equiv) in THF at –50 °C, with *p*-methoxybenzyl bromide (3.0 equiv) in DMF at 0 °C for 20 min produced compound **14** as the only observable regio- and diastereomer in 75% yield. Pd/C-catalyzed selective hydrogenation of **14** (Pd/C 30 wt %,  $H_2$ , 1 atm, EtOAc) produced lactam **15** in 90% yield. Subjecting of ketone-lactam **15** to the  $SmI_2$ -mediated reduction<sup>3b,14</sup> ( $SmI_2$  5 equiv, HMPA 25 equiv, MeOH 10 equiv, THF, –78 °C, 12 h) yielded the desired *cis*-diastereomer **16** as the only observable diastereomer in 85% yield. The spectral data of our synthetic **16** matched those reported for the racemic **16**,<sup>5d</sup> which confirmed the relative stereochemistry of our synthetic product.

We next turned our attention to the stereoselective  $\alpha$ -amination of lactam **16**. Thus, the hydroxyl group in **16** was first protected (TBSOTf,  $NEt_3$ ,  $CH_2Cl_2$ , 93%) as TBS

(13) Ghosh, A. K.; Cappiello, J.; Shin, D. *Tetrahedron Lett.* **1998**, *39*, 4651–4654.


(14) For recent reviews on  $SmI_2$ , see: (a) Procter, D. J.; Flowers, R. A.; Skrydstrup, T., Eds. *Organic Synthesis Using Samarium Diodide: A Practical Guide*; Royal Society of Chemistry Publishing: 2010. (b) Nicolaou, K. C.; Ellery, S. P.; Chen, J. S. *Angew. Chem., Int. Ed.* **2009**, *48*, 7140–7165. (c) Gopalaiah, K.; Kagan, H. B. *New J. Chem.* **2008**, *32*, 607–637.

**Scheme 6. Diastereoselective Synthesis of Compound 16****Scheme 7. Synthesis of Compound 17**

ether **2** (Scheme 7). Successive treatment of lactam **2** with LDA (3.0 equiv) and TrisN<sub>3</sub> (3 equiv) at  $-78\text{ }^\circ\text{C}$  for 5 min, followed by addition of HOAc, led to the formation of the desired azide **17** as a separable diastereomeric mixture in a 3:1 ratio with a combined yield of 90%. The stereochemistry of the major diastereomer **17**, which was assumed to be formed by approaching the electrophile from the less hindered  $\beta$ -face, was determined by NOESY experiments.

To convert the azido group to the *N*-methylamino group, azide **17** was hydrogenated (10% Pd/C 30 wt %, H<sub>2</sub> 1 atm) in the presence of Boc<sub>2</sub>O (1.2 equiv), which gave

the concomitantly protected compound **18** in 90% yield (Scheme 8). Treatment of compound **18** with a large excess of LiAlH<sub>4</sub> (30 equiv) in THF at  $60\text{ }^\circ\text{C}$  for 16 h afforded the amino-diol **19** in 92% yield. It is worth noting that, in this scenario, *N*-Boc reduction to give *N*-Me group, lactam reduction to give pyrrolidine, and *O*-desilylation occurred sequentially. The <sup>1</sup>H and <sup>13</sup>C NMR spectral data of compound **19** are in agreement with those reported by Ciufolini.<sup>2d</sup> Since compound **19** has been converted into FR901483 (**1**) in three steps,<sup>2d</sup> our synthetic approach thus constitutes a formal total synthesis of (–)-FR901483 (**1**).

**Scheme 8. Synthesis of the Known Precursor (19) of FR901483**

In summary, starting from the known chiron **6**, we have achieved the synthesis of the advanced intermediate **19** in 18 steps with an overall yield of 4.1%, which constitutes a formal enantioselective total synthesis of FR901483 (**1**).

**Acknowledgment.** The authors are grateful to the NSF of China (20832005, 21072160), the National Basic Research Program (973 Program) of China (Grant No. 2010CB833200), and the Fundamental Research Funds for the Central Universities of China (Grant No. 201112G001) for financial support. We are grateful to Prof. Dr. L.-F. Xie (Xiamen University) for valuable discussions.

**Supporting Information Available.** Full experimental procedures; <sup>1</sup>H and <sup>13</sup>C NMR spectra of all new compounds; NOESY spectra of compounds **9** and **17**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The authors declare no competing financial interest.